Switch to:
More From Other Websites
XBI Mid-Caps: Seattle Genetics Rose Due to Higher Trading Volumes May 27 2016
Seattle Genetics Starts Trial on Acute Myeloid Leukemia Drug May 26 2016
SEATTLE GENETICS INC /WA Files SEC form 8-K, Change in Directors or Principal Officers, Submission... May 25 2016
Seattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirine (SGN-CD33A) for Patients... May 25 2016
A Scarcity of Biotech Assets for Buyouts? May 20 2016
ETF’s with exposure to Seattle Genetics, Inc. : May 19, 2016 May 19 2016
Seattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : May 18,... May 18 2016
SEATTLE GENETICS INC /WA Files SEC form 8-K, Change in Directors or Principal Officers May 13 2016
SEATTLE GENETICS INC /WA Financials May 05 2016
ETF’s with exposure to Seattle Genetics, Inc. : May 4, 2016 May 04 2016
Seattle Genetics to Present at Upcoming Investor Conferences May 04 2016
Seattle Genetics gears up for big expansion of cancer drug pipeline May 02 2016
Seattle Genetics, Inc. :SGEN-US: Earnings Analysis: Q1, 2016 By the Numbers May 02 2016
Seattle Genetics’ Valuation: How Does It Compare? Apr 30 2016
Seattle Genetics, Alder BioPharmaceuticals report losses Apr 29 2016
SEATTLE GENETICS INC /WA Files SEC form 10-Q, Quarterly Report Apr 29 2016
Seattle Genetics (SGEN) Posts Wider-than-Expected Q1 Loss Apr 29 2016
Edited Transcript of SGEN earnings conference call or presentation 28-Apr-16 8:30pm GMT Apr 29 2016
Seattle Genetics reports 1Q loss Apr 28 2016


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK